Concepedia

Publication | Closed Access

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

DOI

109

Citations

25

References

2014

Year

Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor N. Saleh, Donald Thornton
Clinical Cancer Research

Abstract

LY2510924 demonstrated CD34(+) cell mobilization at doses ≥2.5 mg/day with a tolerable safety profile up to an MTD of 20 mg/day.

References

YearCitations

Page 1